NCT01581658View on ClinicalTrials.gov

Renal Impairment Study of Empagliflozin (BI10773) in Japanese Patients With Type 2 Diabetes

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

April 1, 2012

Primary Completion Date

November 1, 2012

Study Completion Date

November 1, 2012

Conditions
Diabetes Mellitus, Type 2
Interventions
DRUG

BI10773

BI10773 medium dose tablet single dose

DRUG

BI10773

BI10773 medium dose tablet single dose

DRUG

BI10773

BI10773 medium dose tablet single dose

DRUG

BI10773

BI10773 medium dose tablet single dose

Trial Locations (1)

Unknown

1245.53.001 Boehringer Ingelheim Investigational Site, Kurume, Fukuoka

Sponsors
All Listed Sponsors
collaborator

Eli Lilly and Company

INDUSTRY

lead

Boehringer Ingelheim

INDUSTRY